Media headlines about CareDx (NASDAQ:CDNA) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.0505423456394 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- ETFs with exposure to CareDx, Inc. : September 14, 2017 (finance.yahoo.com)
- CareDx, Inc. :CDNA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 (finance.yahoo.com)
- CareDx, Inc. (CDNA) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Zacks Investment Research Lowers CareDx, Inc. (CDNA) to Hold (americanbankingnews.com)
Several equities analysts have recently commented on CDNA shares. Zacks Investment Research cut shares of CareDx from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. ValuEngine raised shares of CareDx from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 24th.
CareDx (NASDAQ:CDNA) traded up 8.79% during midday trading on Friday, reaching $2.97. 221,375 shares of the company traded hands. CareDx has a 12 month low of $0.76 and a 12 month high of $4.42. The firm’s market capitalization is $66.95 million. The firm’s 50 day moving average price is $2.18 and its 200 day moving average price is $1.51.
CareDx (NASDAQ:CDNA) last issued its earnings results on Thursday, August 10th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). CareDx had a negative net margin of 61.27% and a negative return on equity of 85.68%. The business had revenue of $12.05 million for the quarter, compared to analyst estimates of $11.87 million. On average, analysts expect that CareDx will post ($0.82) earnings per share for the current year.
In other CareDx news, major shareholder Neil Gagnon bought 63,120 shares of the firm’s stock in a transaction dated Friday, June 23rd. The shares were acquired at an average cost of $1.10 per share, for a total transaction of $69,432.00. Following the transaction, the insider now owns 886,216 shares in the company, valued at $974,837.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders have bought 130,802 shares of company stock worth $257,457. 5.40% of the stock is owned by company insiders.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.